252 related articles for article (PubMed ID: 17622396)
1. Matrix metalloproteinases and myocardial infarction.
Phatharajaree W; Phrommintikul A; Chattipakorn N
Can J Cardiol; 2007 Jul; 23(9):727-33. PubMed ID: 17622396
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):53-61. PubMed ID: 15782494
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
[TBL] [Abstract][Full Text] [Related]
5. Effects of Matrix Metalloproteinases on the Performance of Platelet Fibrin Gel Spiked With Cardiac Stem Cells in Heart Repair.
Shen D; Tang J; Hensley MT; Li T; Caranasos TG; Zhang T; Zhang J; Cheng K
Stem Cells Transl Med; 2016 Jun; 5(6):793-803. PubMed ID: 27112177
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
7. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
DeLeon-Pennell KY; Meschiari CA; Jung M; Lindsey ML
Prog Mol Biol Transl Sci; 2017; 147():75-100. PubMed ID: 28413032
[TBL] [Abstract][Full Text] [Related]
8. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: an animal experiment with rats].
Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1288-93. PubMed ID: 15387968
[TBL] [Abstract][Full Text] [Related]
9. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
10. Myocardial extracellular matrix remodeling in ischemic heart failure.
Gallagher GL; Jackson CJ; Hunyor SN
Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
[TBL] [Abstract][Full Text] [Related]
11. MMP induction and inhibition in myocardial infarction.
Lindsey ML
Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization.
Eckart RE; Uyehara CF; Shry EA; Furgerson JL; Krasuski RA
J Interv Cardiol; 2004 Feb; 17(1):27-31. PubMed ID: 15009768
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases in patients with acute myocardial infarction.
Hojo Y; Ikeda U; Ueno S; Arakawa H; Shimada K
Jpn Circ J; 2001 Feb; 65(2):71-5. PubMed ID: 11216828
[TBL] [Abstract][Full Text] [Related]
14. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
15. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
16. Cardiomyocyte dimethylarginine dimethylaminohydrolase1 attenuates left-ventricular remodeling after acute myocardial infarction: involvement in oxidative stress and apoptosis.
Hou L; Guo J; Xu F; Weng X; Yue W; Ge J
Basic Res Cardiol; 2018 Jun; 113(4):28. PubMed ID: 29892894
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
18. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition.
Purcell BP; Lobb D; Charati MB; Dorsey SM; Wade RJ; Zellars KN; Doviak H; Pettaway S; Logdon CB; Shuman JA; Freels PD; Gorman JH; Gorman RC; Spinale FG; Burdick JA
Nat Mater; 2014 Jun; 13(6):653-61. PubMed ID: 24681647
[TBL] [Abstract][Full Text] [Related]
19. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction.
Tessone A; Feinberg MS; Barbash IM; Reich R; Holbova R; Richmann M; Mardor Y; Leor J
Cardiovasc Drugs Ther; 2005 Dec; 19(6):383-90. PubMed ID: 16435072
[TBL] [Abstract][Full Text] [Related]
20. Targeting MMP-2 to treat ischemic heart injury.
Hughes BG; Schulz R
Basic Res Cardiol; 2014 Jul; 109(4):424. PubMed ID: 24986221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
